Esperion Q3 revenue $51.6M (+52% YoY); net loss narrows to $29.5M

Esperion Therapeutics, Inc.

2024-Q3 EPS reported -$0.17 revenue$263,201,000

Total revenue $51.6M (+52% YoY); U.S. net product revenue $31.1M (+53% YoY).
Net loss $29.5M (EPS -$0.15) vs. $41.3M loss (-$0.37) in Q3 2023.
Cash & equivalents $144.7M at Sep 30, up from $82.2M at Dec 31, 2023.
Retail prescription equivalents +12% QoQ; Oct 2024 TRx +17% vs. first 4 weeks of Q3.
European partner DSE royalty revenue $8.9M (+19% sequentially); Otsuka on track for Japan NDA filing by end 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.